CN101042336A - Ischemia modified albumin measuring reagent - Google Patents
Ischemia modified albumin measuring reagent Download PDFInfo
- Publication number
- CN101042336A CN101042336A CNA2006100317498A CN200610031749A CN101042336A CN 101042336 A CN101042336 A CN 101042336A CN A2006100317498 A CNA2006100317498 A CN A2006100317498A CN 200610031749 A CN200610031749 A CN 200610031749A CN 101042336 A CN101042336 A CN 101042336A
- Authority
- CN
- China
- Prior art keywords
- value
- albumin
- ischemia
- damping fluid
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
This invention relates to one ischaemia modification albumin test agent, which is processed by the following steps: with original materials as cobalt chloride for 0.001-1%, alcaine triethanolamine buffer liquid for 99-99.999% with ph value as 7.0-9.0; solving the above cobalt chloride into the buffer liquid to get mixture liquid of the test agent. the test agent is for acute myocardial ischemia dialogue aids to exclude the acute coronary syndrome and ACS danger layer with enlarging needs.
Description
Technical field
The present invention relates to a kind of medical clinical chemistry external diagnosis reagent, especially a kind of reagent that is used for the mensuration of ischemia modified albumin IMA.
Background technology
Ischemia modified albumin IMA (Ischemia-modified albumin, be called for short IMA) be meant at clinical ischemic or pour into medical procedure again when taking place, cause the binding ability of albumin and transition metal to change owing to free radical etc. has destroyed sero-abluminous amino acid sequence, this albumin that takes place to change with the transition metal binding ability because of ischemic is called ischemia modified albumin IMA.
Human serum albumins (Human serum albumin is called for short HSA) is a kind of circulating protein, is made up of 585 amino acid sequences (66500Da), and its amino terminal (N-terminus) is human peculiar one section sequence.Have and studies confirm that the amino terminal of HSA is transition metals cobalt, the isoionic binding site of copper and mickel.The binding site of last these metals of HSA, site are compared with the albumin of other animals and are degraded by biochemical factor easily and destroy.When ischemic took place, the sodium pump that cell is interior and the extracellular oxygen supply reduces, acidic metabolite increases, the cell membrane energy relies on destroyed, calcium pump is out of control, and these factors will cause the structural change of HSA amino terminal, made the binding ability reduction of HSA and metal.The perfusion again that takes place behind the of short duration ischemic can produce a large amount of free radicals, free copper ion and ferric ion expose simultaneously, to further increase the weight of this change of HSA, this be body " sacrifice " albumin with to anti-hypoxia, avoid and reduce as far as possible a kind of mechanism of tissue damage.
After prior art is mainly passed through to measure the albumin bound cobalt, the variation of the absorbance of the concentration of residue cobalt, the concentration of indirect calculation IMA, at present, neither one the recognized standard product, so each manufacturer can have diverse ways to come indirect determination IMA.
Summary of the invention
The technical problem to be solved in the present invention is, the defective at prior art exists proposes a kind of reagent that is used for ischemia modified albumin measuring, this reagent superior performance, and accuracy, degree of accuracy is good and lower cost.
Technical solution of the present invention is, described albumin combination mensuration reagent of ischemia modification adopts following raw material and technology to make, and material composition is:
Cobalt chloride 0.001～1%,
PH value is 7.0～9.0 Triethanolammonium chloride damping fluid 99～99.999%.
The pH value that the cobalt chloride of above-mentioned weight item is dissolved in above-mentioned weight item is that the gained mixed solution promptly gets albumin combination mensuration reagent of ischemia modification after filtration in 7.0～9.0 the Triethanolammonium chloride damping fluid.
Above-mentioned pH value is that 7.0～9.0 Triethanolammonium chloride damping fluid also can be that pH value is that 7.0～9.0 phosphate buffer or pH value are that 7.0～9.0 trihydroxy aminomethane buffer solution or pH value are 7.0～9.0 barbitol buffer solution.
The design of above-mentioned albumin combination mensuration reagent of ischemia modification and the following principle of use foundation:
1) standard items definition: every milliliter of serum is 1 unit in conjunction with the divalent cobalt ion of 1 μ g.The standard items preparation;
2) accurately measure cobalt ions (Co
2+) concentration, albumin consumes Co in every milliliter of standard items of absorbance change calculations of bioassay standard product then
2+μ g number, thereby obtain the value of standard items.Ischemia modified albumin IMA is to Co
2+Binding ability is lower than normal albumin, albumin and Co in the serum
2+In conjunction with after, remaining free cobalt ions (Co
2+) generate bronzing product, colorimetric under the wavelength of 470～510nm, its absorbance and Co with dithiothreitol (DTT) (DTT) reaction
2+Concentration is directly proportional, and compares with standard items, can calculate the concentration of ACB in the sample (albumin cobalt binding ability).
The present invention must meet the product technology standard (Registering product standard No.: YZB/ Hunan 0010-2006), reach following technical indicator:
Linear range 0～180U/ml
Withinrun precision CV≤4.5%
Betweenrun precision CV≤5.0%
Blank absorbency 〉=1.0A
Accuracy: desired value ± 10%
Examination and test of products method is according to the Registering product standard No.: content inspection shown in the 0010-2006 of YZB/ Hunan.
The invention has the beneficial effects as follows:
1. social benefit: the mensuration of ischemia modified albumin IMA is important indicator in the clinical biochemical.The albumin combination mensuration reagent of ischemia modification desired use is the auxiliary diagnosis to acute myocardial ischemia, gets rid of the dangerous layering of acute coronary artery syndrome (ACS) and ACS.
2. economic benefit: along with the raising and the clinical needs of medical diagnosis technical merit, product consumption will heighten.A high economic benefit can be expected fully.
Embodiment:
Embodiment 1: a kind of embodiment product of the present invention adopts following raw material and technology to make:
Prescription: cobalt chloride 0.001kg,
Triethanolammonium chloride damping fluid (PH 7.0) 99.999kg.
Preparation: above-mentioned 0.001kg cobalt chloride is inserted dissolving in the jar that fills above-mentioned 99.999kg Triethanolammonium chloride damping fluid, and the gained mixed solution is albumin combination mensuration reagent of ischemia modification after filtration.
Embodiment 2: another kind of embodiment product of the present invention adopts following raw material and technology to make:
Prescription: cobalt chloride 1g,
Triethanolammonium chloride damping fluid (PH 9.0) 99g.
Preparation: above-mentioned 1g cobalt chloride is inserted dissolving in the jar that fills above-mentioned 99g Triethanolammonium chloride damping fluid, and the gained mixed solution is albumin combination mensuration reagent of ischemia modification after filtration.
Ischemia modified albumin IMA (IMA) the mensuration reagent that the present invention abides by the WS/T 124-1999 reagent quality test stone development of health competent authorities formulation has reached the designing quality requirement.The result shows, can improve acute myocardial ischemia patient's early stage ischemia test sensitivity.This reagent has produced good social benefit and economic benefit.At present pilot production with albumin-cobalt in conjunction with the test (Albumin cobalt binding assay ACB) detects IMA.The ischemia modified albumin IMA (IMA) of the present invention's development is measured reagent by long-term on probation, has proved to reach designing requirement, meets every index promulgated by the ministries or commissions of the Central Government.Product adopts at random sample 200 examples to test through clinical laboratory of Chinese Xiangye No. 2 Hospital of Central South University, clinical laboratory of Hunan China province tumour hospital, and test result is good.
Claims (2)
1, a kind of albumin combination mensuration reagent of ischemia modification adopts following raw material and technology to make, and material composition is:
Cobalt chloride 0.001～1%,
PH value is 7.0～9.0 Triethanolammonium chloride damping fluid 99～99.999%,
The pH value that the cobalt chloride of mentioned component is dissolved in mentioned component is that the gained mixed solution is finished product after filtration in 7.0～9.0 the Triethanolammonium chloride damping fluid.
2, albumin combination mensuration reagent of ischemia modification according to claim 1, it is characterized in that described pH value is that 7.0～9.0 Triethanolammonium chloride damping fluid also can be that pH value is that 7.0～9.0 phosphate buffer or pH value are that 7.0～9.0 trihydroxy aminomethane buffer solution or pH value are 7.0～9.0 barbitol buffer solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100317498A CN101042336A (en) | 2006-05-31 | 2006-05-31 | Ischemia modified albumin measuring reagent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100317498A CN101042336A (en) | 2006-05-31 | 2006-05-31 | Ischemia modified albumin measuring reagent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101042336A true CN101042336A (en) | 2007-09-26 |
Family
ID=38808012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100317498A Pending CN101042336A (en) | 2006-05-31 | 2006-05-31 | Ischemia modified albumin measuring reagent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101042336A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102323255A (en) * | 2011-05-30 | 2012-01-18 | 吉权 | Ischemia modified albumin determination colour-developing agent and preparation method thereof |
| CN102539206A (en) * | 2011-12-02 | 2012-07-04 | 宁波美康生物科技股份有限公司 | Preparation method of quality control serum for ischemia-modified albumin |
| RU2462762C1 (en) * | 2011-07-08 | 2012-09-27 | Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации | Method for simulating chronic toxic arterial hypertension and cardiopathy in experimental animals |
| CN101458257B (en) * | 2007-12-12 | 2012-12-05 | 上海复星医药（集团）股份有限公司 | Kit for detecting ischemia modified albumin and method for making same |
| CN103344768A (en) * | 2013-07-10 | 2013-10-09 | 中国人民解放军第三军医大学第一附属医院 | Ischemic heart disease detection kit and application thereof |
| CN103558398A (en) * | 2013-11-04 | 2014-02-05 | 山东博科生物产业有限公司 | Anti-heparan-interference ischemia modified albumin detection reagent |
| CN103760357A (en) * | 2013-11-04 | 2014-04-30 | 山东博科生物产业有限公司 | Detection kit for ischemia modified albumin |
| CN108152225A (en) * | 2017-11-29 | 2018-06-12 | 武汉生之源生物科技股份有限公司 | The assay method and detection kit of a kind of ischemia modified albumin IMA |
-
2006
- 2006-05-31 CN CNA2006100317498A patent/CN101042336A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101458257B (en) * | 2007-12-12 | 2012-12-05 | 上海复星医药（集团）股份有限公司 | Kit for detecting ischemia modified albumin and method for making same |
| CN102323255A (en) * | 2011-05-30 | 2012-01-18 | 吉权 | Ischemia modified albumin determination colour-developing agent and preparation method thereof |
| CN102323255B (en) * | 2011-05-30 | 2013-08-14 | 吉权 | Ischemia modified albumin determination colour-developing agent and preparation method thereof |
| RU2462762C1 (en) * | 2011-07-08 | 2012-09-27 | Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации | Method for simulating chronic toxic arterial hypertension and cardiopathy in experimental animals |
| CN102539206A (en) * | 2011-12-02 | 2012-07-04 | 宁波美康生物科技股份有限公司 | Preparation method of quality control serum for ischemia-modified albumin |
| CN103344768A (en) * | 2013-07-10 | 2013-10-09 | 中国人民解放军第三军医大学第一附属医院 | Ischemic heart disease detection kit and application thereof |
| CN103344768B (en) * | 2013-07-10 | 2015-05-20 | 中国人民解放军第三军医大学第一附属医院 | Ischemic heart disease detection kit and application thereof |
| CN103558398A (en) * | 2013-11-04 | 2014-02-05 | 山东博科生物产业有限公司 | Anti-heparan-interference ischemia modified albumin detection reagent |
| CN103760357A (en) * | 2013-11-04 | 2014-04-30 | 山东博科生物产业有限公司 | Detection kit for ischemia modified albumin |
| CN103760357B (en) * | 2013-11-04 | 2016-02-03 | 山东博科生物产业有限公司 | A kind of ischemia modified albumin IMA detection kit |
| CN108152225A (en) * | 2017-11-29 | 2018-06-12 | 武汉生之源生物科技股份有限公司 | The assay method and detection kit of a kind of ischemia modified albumin IMA |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101042336A (en) | Ischemia modified albumin measuring reagent | |
| JP4515786B2 (en) | Method for reducing the influence of hematocrit on the measurement of an analyte in whole blood, and a test kit and a test article useful in the method | |
| Jesudason et al. | Mechanical forces regulate elastase activity and binding site availability in lung elastin | |
| WO2008070865A3 (en) | Materials and methods for efficient and accurate detection of analytes | |
| EP2391893B1 (en) | Lyophilised dabigatran | |
| CN1959377A (en) | Albumin combination mensuration reagent of ischemia modification, and method of application | |
| Liu et al. | A polymyxin B–silver nanoparticle colloidal system and the application of lipopolysaccharide analysis | |
| Chen et al. | A fluorescent sensor constructed from nitrogen-doped carbon nanodots (N-CDs) for pH detection in synovial fluid and urea determination | |
| WO2008021103A3 (en) | Systems and methods for measuring and improving blood chemistry | |
| Wang et al. | In situ synthesis of fluorescent copper nanoclusters for rapid detection of ascorbic acid in biological samples | |
| Chen et al. | A glucose-activatable trimodal glucometer self-assembled from glucose oxidase and MnO 2 nanosheets for diabetes monitoring | |
| Duong et al. | Detection of arginase through the optical behaviour of liquid crystals due to the pH-dependent adsorption of stearic acid at the aqueous/liquid crystal interface | |
| Wang et al. | Evaluating diabetic ketoacidosis via a MOF sensor for fluorescence imaging of phosphate and pH | |
| EP2175276B1 (en) | Raman-detection based analysis for glucose products using pyridinylboronic acid | |
| CN109668863B (en) | Copper ion detection method based on graphene and click chemistry, kit and application thereof | |
| Hirayama et al. | Properties of calcium phosphate cements with different tetracalcium phosphate and dicalcium phosphate anhydrous molar ratios | |
| WO2003069341A3 (en) | Method of diagnosis of inflammatory diseases using calgranulin c | |
| Zhu et al. | Electrochemical determination of ascorbic acid based on hydrothermal synthesized ZnO nanoparticles | |
| CN1959378A (en) | Albumin combination mensuration reagent of ischemia modification | |
| Sharda et al. | Protection of lead-induced cytotoxicity using paramagnetic nickel–insulin quantum clusters | |
| Jiang et al. | A new immune resonance scattering spectral assay for trace fibrinogen with gold nanoparticle label | |
| Idogun et al. | Assessment of microalbuminuria and glycated hemoglobin in type 2 diabetes mellitus complications | |
| CN102890066A (en) | Kit for detecting total antioxidant capacity | |
| RU2425382C1 (en) | Method of blood plasma proximate analysis for cardiomyoglobin by means of electrochemical immunosensor | |
| CN103674938A (en) | Ischemia-modified albumin combination determination reagent, determination method and kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |